Name: Domen Ribnikar, MD
Last 2 Hospitals/Depts: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network (fellowship)
610 University Avenue, M5G 2M9, Toronto, Ontario, Canada
Institute of Oncology Ljubljana, Medical Oncology Department, Zaloska cesta 2, 1000
Ljubljana, Slovenia (current position)
(June 19 th 2008): Graduated from Medical Faculty of Ljubljana, Slovenia – Doctor of Medicine, with average grade of 8.5 (grading from 6 – 10)
(August 1 st 2008 – January 31 st 2009): Internship at General Hospital Jesenice, concluded with professional examination
(February 1 st 2009 – August 31 st 2009): Internship at the Institute of Oncology Ljubljana, Medical Oncology Department
(September 1 st 2009 – May 31 st 2015): Residency of Medical Oncology at the Institute of Oncology Ljubljana, Slovenia
(October 1 st 2012 – present): Postgraduate PhD studies in Biomedicine at the Medical Faculty of Ljubljana, Slovenia
(June 1 st 2014 – November 1 st 2014): Fellowship (a breast cancer research fellow) under the supervision of Fatima Cardoso, MD, in the Champalimaud cancer center in Lisbon, Portugal, Breast Unit
(June 1 st 2015 – August 31 st 2016): A medical oncologist at the Institute of Oncology Ljubljana, Slovenia
(September 10 th 2016 – September 1 st 2018): Clinical research Fellowship in the Breast Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
November 1 st 2018 – present: Medical oncologist at the Institute of Oncology Ljubljana, Slovenia
Peer reviewed publications
RIBNIKAR, Domen, FINK, Špela, FRKOVIĆ-GRAZIO, Snježana, LEŠNIČAR, Hotimir, SADIKOV, Aleksander, ČUFER, Tanja. Potek bolezni pri bolnicah s HER-2 pozitivnim rakom dojk. Onkologija (Ljubl.), 2008, yr 12, No 2, pp. 94-8. [COBISS.SI-ID 25343193]
Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F. Breast cancer under age 40: a different approach. Curr Treat Options Oncol. 2015 Apr;16(4):334.
Sousa B, Ribeiro JM, Ribnikar D, Cardoso F. Metastatic Breast Cancer. Chapter in Management of Breast Diseases. January 2016; pp 451-74.
Ribnikar D, Cardoso F. Tailoring Chemotherapy in Early-Stage Breast Cancer: Based on Tumor Biology or Tumor Burden? Am Soc Clin Oncol Educ Book. 2016; 35:e31-8.
Ribnikar D, Sousa B, Cufer T, Cardoso F. Extended adjuvant endocrine therapy – A standard to all or some? Breast. 2017. Apr; 32:112-18. (https://pubmed.ncbi.nlm.nih.gov/28152498/)
Ribnikar D, Ratosa I, Perhavec A, Amir E. General Overview and Treatment Recommendations for Young Women with Breast Cancer. Rev Invest Clin. 2017 Mar-Apr; 69(2):77-93.
Goldvaser H, Ribnikar D, Fazelzad R, Seruga B, Templeton AJ, Ocana A, Amir E. Influence of non-measurable disease on progression-free survival in patients with metastatic breast cancer.
Cancer Treat Rev. 2017 Sep; 59: 6-53. (https://pubmed.ncbi.nlm.nih.gov/28734183/)
Goldvaser H, AlGorashi I, Ribnikar D, Seruga B, Templeton AJ, Ocana A, Amir E. Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: A systematic review and meta-analysis. Cancer Treat Rev. 2017 Aug 24; 60: 53-9. (https://pubmed.ncbi.nlm.nih.gov/28881223/)
Goldvaser H, Barnes TA, Šeruga B, Cescon DW, Ocaña A, Ribnikar D, Amir E. Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. J Natl Cancer Inst. 2018 Jan 1;110(1).
Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Reporting of Randomized Trials in Common Cancers in the Lay Media. Oncology. 2018; 94(2): 65-71. (https://pubmed.ncbi.nlm.nih.gov/29151109/)
Ribnikar D, Bedard PL. Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer. Future Oncol. 2017; 13(30): 2733-36.
Goldvaser H, Majeed H, Ribnikar D, Seruga B, Ocana A, Cescon DW, Amir E. Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. Breast Cancer Res Treat. 2018; 169(3): 413-25.
Algorashi I, Goldvaser H, Ribnikar D, Cescon DW, Amir E. Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treat Rev. 2018; 70: 138-43.
Ribnikar D, Volovat SR, Cardoso F. Targeting CDK 4/6 pathways and beyond in breast cancer.
Breast. 2019; 43: 8-17.
Goldvaser H, Ribnikar D, Majeed H, Ocaña A, Amir E. Absolute benefit from adjuvant chemotherapy in contemporary clinical trials: A systemic review and meta-analysis. Cancer Treat Rev. 2018; 71: 68-75.
Veitch Z, Khan OF, Tilley D, Ribnikar D, Kostaras X, King K, Tang P, Lupichuk S. Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer. J Natl Compr Canc Netw. 2019; 17(1): 47-56.
Goldvaser H, Korzets Y, Shepshelovich D, Yerushalmi R, Sarfaty M, Ribnikar D, Thavendiranathan P, Amir E. Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectr. 2019; 11;3(2):pkz033.
Veitch Z, Khan OF, Tilley D, Tang PA, Ribnikar D, Stewart DA, Kostaras X, King K, Lupichuk S. Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer. J Natl Compr Canc Netw. 2019 Aug 1;17(8):957-67.
Ratosa I, Orazem M, Scoccimarro E, Steinacher M, Dominici L, Aquilano M, Cerbai C, Desideri I, Ribnikar D, Marinko T, Livi L, Meattini I. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2020 May 26:S1526-8209(20)30115-4. (https://pubmed.ncbi.nlm.nih.gov/32622736/)
Saleh RR, Meti N, Ribnikar D, Goldvaser H, Ocana A, Templeton AJ, Seruga B, Amir E. Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors. Cancer Med. 2020 Sep 4.
Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ. Association of obesity with breast cancer outcome in relation to cancer subtypes: A Meta-analysis. J Natl Cancer Inst. 2021; Feb 23.
Ribnikar D, Stukalin I, Bedard PL, Hamilton RJ, Jewett M, Warde P, Chung P, Anson-Cartwright L, Templeton AJ, Amir E, Hansen AR, Heng D YC, Lewin J. The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer. Curr Oncol. 2020; Dec 21; 28 (1): 107-14.
Ribnikar D, Goldvaser H, Veitch ZW, Ocana A, Templeton AJ, Šeruga B, Amir E. Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade. Sci Rep. 2021 May 25;11(1):10843.
Veitch Z, Ribnikar D, Tilley D, Tang PA, King K, Bedard PL, Lupichuk S, Cescon DW. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. Br J Cancer. 2022 Apr; 126 (6): 881-8.
Blatnik A, Ribnikar D, Šetrajčič Dragoš V, Novaković S, Stegel V, Grčar Kuzmanov B, Boc N, Perić B, Škerl P, Klančar G, Krajc M. BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome. Case Reports. Breast Cancer. 2022, Sep; 29 (5): 921-7.
Ratosa I, Dobnikar N, Bottosso M, Vittoria Dieci M, Jacot W, Pouderoux S, Ribnikar D, Sinoquet L, Guarneri V, Znidaric T, Darlix A, Griguolo G. Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort. Int J Cancer. 2022. Oct 15; 151 (8): 1355-66.
Visani L, Livi L, Ratosa I, Orazem M, Ribnikar D, Saieva C, Becherini C, Salvestrini V, Scoccimarro E, Valzano M, Cerbai C, Desideri I, Bernini M, Orzalesi L, Nori J, Bianchi S, Morandi A, Meattini I. Safety of CDK 4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. Radiother Oncol. 2022; 177: 40-5. (https://pubmed.ncbi.nlm.nih.gov/36349599/)
December 2007: Medical Faculty Prešeren Award for Research Work – The clinical course of HER-2 positive breast cancer patients
June 2013: Award for poster presentation of clinical cohort study which was presented by Domen Ribnikar on his own in Opatija, as a part of CEOC 2013: Prognosis of two cohorts of HER-2 positive breast cancer patients not being treated with adjuvant antiHER-2 therapy: patients with small tumors and polimorbid patients
ESMO examination (Amsterdam 2013): achieved a great success in the ESMO Examination held on the 28 th of September in Amsterdam, Netherlands (ranking the 8 th of 268 candidates)
September 2017: ESMO congress in Madrid, Spain: received the Best poster award for the original research entitled Reporting of randomized trials in common cancers in the lay media
May 2018: 2017-2018 Citizenship Award Runner up, Division of Medical Oncology and Hematology, Toronto, Canada, Ontario
June 2022: A national award for best oncologist in Slovenia in 2022 (patients’ decision).
Date of signature: December 28 2022